{
  "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
  "docSlug": "97e34d6c4db7d9454440fee3efd43545",
  "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
  "authorId": "axcella-health",
  "authorName": "Axcella Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 22,
  "pageCount": 62,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 9,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/22",
  "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
  "deckJsonHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61.json",
  "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.38,
        "w": 0.94,
        "x": 0.03,
        "y": 0.0011799999999999998
      },
      "kind": "chart",
      "text": "Liver stiffness, ALT, and MRI PDFF results comparing Placebo, AXA1125 22.6 BID, and AXA1125 33.9 BID.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6d674b-cb23-405e-90a0-15453a699278",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.0057
      },
      "kind": "list",
      "text": "Significant effects on liver stiffness comparable to or better than other agents in ph2b/3\nContinued demonstration of effects on relevant pathways of NASH biology\nObserved safety and tolerability pattern consistent with high safety margin\nBoth doses are active, and effects consistent in overall population and T2DM\nResults position AXA1125 to be potential first line treatment in NASH",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ac22253-ddf2-4198-a74d-7151e4379be5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Summary of Results From this Interim Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae9cd93b-2b8d-4e07-90c2-8c7a3338846a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 36,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "de6af44a-f17d-4c55-adca-ab6e25c41e5d",
      "evidence": "The presentation highlights the need for effective treatment options and the risks associated with disease progression",
      "position": 0,
      "objective": "What is the risk of not treating NASH effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}